Lesion volume change after treatment with tissue plasminogen activator can discriminate clinical responders from nonresponders

Stroke

Volumn 38, Issue 11, 2007, Pages 2919-2923

  Merino, José G ^a   Latour, Lawrence L ^a   Todd, Jason W ^a,b   Luby, Marie ^a   Schellinger, Peter D ^a,c   Kang, Dong Wha ^a,d   Warach, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Carolinas Medical Center NorthEast   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute stroke; Brain imaging; Brain infarction; MRI; Thrombolysis; Thrombolytic RX

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN RADIOGRAPHY; BRAIN SIZE; CONVALESCENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANKIN SCALE; RATING SCALE; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BRAIN; BRAIN INFARCTION; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 35649009853     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.485995     Document Type: Article

References (17)

1. Schlaug G, Siewert B, Benfield A, Edelman RR, Warach S. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke. Neurology. 1997;49:113-119.
2. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Vespa P, Kalafut M, Alger JR. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462-469.
3. Lansberg MG, O'Brien MW, Tong DC, Moseley ME, Albers GW. Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol. 2001;58:613-617.
4. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, Gerraty RP, Tress BM, Wright PM, Donnan GA, Davis SM. Diffusion-and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 2002;51:28-37.
5. Fiehler J, Foth M, Kucinski T, Knab R, von Bezold M, Weiller C, Zeumer H, Rother J. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke. 2002;33:79-86.
6. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 investigators. Ann Neurol. 2000;48:713-722.
7. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
8. Warach S, Kaufman D, Chiu D, Devlin T, Luby M, Rashid A, Clayton L, Kaste M, Lees KR, Sacco R, Fisher M. Effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: the GAIN MRI substudy. Cerebrovasc Dis. 2006;21:106-111.
9. Kang DW, Chalela JA, Dunn W, Warach S. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke. 2005;36:1939-1943.
10. Weisskoff RM, Chesler D, Boxerman JL, Rosen BR. Pitfalls in MR measurement of tissue blood flow with intravascular tracers: which mean transit time? Magn Reson Med. 1993;29:553-558.
11. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
12. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Warach S. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112.
13. Luby M, Bykowski JL, Schellinger PD, Merino JG, Warach S. Intra- and inter-rater reliability of ischemic lesion volumes measurements on diffusion-weighted, mean transit time, and fluid-attenuated inversion recovery MRI. Stroke. 2006;37:2951-2956.
14. Menezes NM, Ay H, Zhu MW, Lopez CJ, Singhal AB, Karonen JO, Aronen HJ, Liu Y, Nuutinen J, Koroshetz WJ, Sorensen AG. The real estate factor: quantifying the impact of infarct location on stroke severity. Stroke. 2007;38:194-197.
15. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol. 1999;46:568-578.
16. Pialat JB, Wiart M, Nighoghossian N, Adeleine P, Derex L, Hermier M, Froment JC, Berthezene Y. Evolution of lesion volume in acute stroke treated by intravenous tPA. J Magn Reson Imaging. 2005;22:23-28.
17. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <-6 hours. Stroke. 2002;33:2438-2445.